Genfit S.A. Total Liabilities
Genfit S.A. total liabilities. Based on the latest financial reports, Genfit S.A. (GNFT) has total liabilities worth €181.58 Million EUR (≈ $212.28 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Genfit S.A. (GNFT) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Genfit S.A. (2003–2025)
Total liabilities of Genfit S.A. from 2003 to 2025. This chart illustrates how Genfit S.A.'s total liabilities have evolved over time, based on quarterly financial data. Explore Genfit S.A. (GNFT) investment intensity to see how much of total assets are deployed in long-term investments.
Genfit S.A. Competitors by Total Liabilities
The table below lists competitors of Genfit S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sichuan Tianyi Comheart Telecom Co Ltd Class A
SHE:300504
|
China | CN¥569.44 Million |
|
V-Mart Retail Limited
NSE:VMART
|
India | Rs16.95 Billion |
|
Shenzhen Sunnypol Optoelectronics Co Ltd
SHE:002876
|
China | CN¥4.13 Billion |
|
Babcock & Wilcox Enterprises Inc
NYSE:BW
|
USA | $942.23 Million |
|
PT Super Bank Indonesia Tbk
JK:SUPA
|
Indonesia | Rp15.85 Trillion |
|
Ningbo Exciton Technology Co Ltd
SHE:300566
|
China | CN¥1.19 Billion |
|
Jiangsu Huachang Chemical Co Ltd
SHE:002274
|
China | CN¥2.48 Billion |
|
Fujian Zhangzhou Development Co Ltd
SHE:000753
|
China | CN¥9.03 Billion |
Liability Composition Analysis (2003–2025)
This chart breaks down Genfit S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see GNFT total assets.
Liquidity & Leverage Metrics
Genfit S.A. Total Liabilities Ratios Explained
Genfit S.A. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.40 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -7.68 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genfit S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genfit S.A. (2003–2025)
The table below shows the annual total liabilities of Genfit S.A. from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €181.58 Million ≈ $212.28 Million |
+120.90% |
| 2024-12-31 | €82.20 Million ≈ $96.10 Million |
-22.39% |
| 2023-12-31 | €105.92 Million ≈ $123.83 Million |
-12.47% |
| 2022-12-31 | €121.01 Million ≈ $141.48 Million |
-25.59% |
| 2021-12-31 | €162.62 Million ≈ $190.12 Million |
-24.28% |
| 2020-12-31 | €214.78 Million ≈ $251.10 Million |
-4.88% |
| 2019-12-31 | €225.79 Million ≈ $263.97 Million |
+8.27% |
| 2018-12-31 | €208.54 Million ≈ $243.80 Million |
+10.36% |
| 2017-12-31 | €188.95 Million ≈ $220.91 Million |
+706.91% |
| 2016-12-31 | €23.42 Million ≈ $27.38 Million |
+69.17% |
| 2015-12-31 | €13.84 Million ≈ $16.18 Million |
-13.15% |
| 2014-12-31 | €15.94 Million ≈ $18.63 Million |
+5.84% |
| 2013-12-31 | €15.06 Million ≈ $17.60 Million |
-10.09% |
| 2012-12-31 | €16.75 Million ≈ $19.58 Million |
-31.97% |
| 2011-12-31 | €24.62 Million ≈ $28.78 Million |
+7.05% |
| 2010-12-31 | €23.00 Million ≈ $26.89 Million |
+0.39% |
| 2009-12-31 | €22.91 Million ≈ $26.78 Million |
-2.98% |
| 2008-12-31 | €23.61 Million ≈ $27.60 Million |
+59.04% |
| 2007-12-31 | €14.85 Million ≈ $17.36 Million |
-19.64% |
| 2006-12-31 | €18.47 Million ≈ $21.60 Million |
+5.88% |
| 2005-12-31 | €17.45 Million ≈ $20.40 Million |
+5.06% |
| 2004-12-31 | €16.61 Million ≈ $19.42 Million |
-2.83% |
| 2003-12-31 | €17.09 Million ≈ $19.98 Million |
-- |
About Genfit S.A.
Genfit S.A., together with its subsidiaries, engages in the research and development of medicines and diagnostic solutions in France and internationally. The company offers elafibranor for the treatment of primary biliary cholangitis; and NIS, a non-invasive diagnostic technology for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops elafibranor, which is in Phase… Read more